0001562180-23-003921.txt : 20230503 0001562180-23-003921.hdr.sgml : 20230503 20230503182615 ACCESSION NUMBER: 0001562180-23-003921 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230501 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carruthers R Michael CENTRAL INDEX KEY: 0001644467 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 23885769 MAIL ADDRESS: STREET 1: 3122 STERLING CIRCLE, SUITE 200 CITY: BOULDER STATE: CO ZIP: 80301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-262-7002 MAIL ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 4 1 primarydocument.xml PRIMARY DOCUMENT X0407 4 2023-05-01 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001644467 Carruthers R Michael C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE BOULDER CO 80303 false true false false Chief Financial Officer false Common Stock 2023-05-01 4 M false 5208.00 0.00 A 17462.00 D Common Stock 2023-05-02 4 S false 1336.00 8.9049 D 16126.00 D Restricted Stock Units 0.00 2023-05-01 4 M false 5208.00 0.00 D 2032-05-01 Common Stock 5208.00 10417.00 D Includes 254 shares purchased on November 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. /s/ John R. Moore Attorney-in-Fact for R. Michael Carruthers 2023-05-03